Sotalol (MJ 1999), a beta-adrenergic blocking agent found to have no significant intrinsic myocardial depressant effects, was adnministered intravenously to 20 patients with heart disease. Eight of the patients had clinical and hemodynamic evidence of chronic heart failure. Doses ranged from 0.2 to 0.6 mg/kg.
Hemodynamics
Myocardial contractility ion effect in isolated cardiac muscle prepara-tionsl3 and to cause hemodynamic changes in the intact animal4-6 and in man,7-10 indicating a depression of ventricular function. For this reason, beta blockade has generally been held to be relatively contraindicated in patients with significant heart failure.
Beta-adrenergic blockade induced by a more recently synthesized agent, sotalol* (MJ 1999), a methanesulfonanilid-substituted iso- propylphenylethylamine"l ( fig. 1 ) has been reported to be essentially free of associated myocardial depressant or negative inotropic effects, as determined by studies in isolated cardiac muscle.2' 2 This study assesses the hemodynamic responses to sotalol of resting *dl 4-( 2-isopropylamino-1-hydroxyethyl) methanesulfonanilide hydrochloride. II   III   IV   III   IV   III   III   II   IV   II   IV   III   II   III   III   II   II   IV   I Abbreviations: AS = aortic stenosis; AR = aortic regurgitation; MS = mitral stenosis; MR = mitral regurgitation; TR = tricuspid regurgitation; CAD = coronary artery disease; NSR = normal sinus rhythm; 2°Blk = second degree A-V block, Wenckebach phenomenon; PE = acute pulmonary embolism; SAS = hypertrophic subaortic stenosis; S/D/M = systolic/diastolic, mean; S/ ED = systolic/end-diastolic; NYHA = New York Heart Association classification; AF = atrial fibrillation; AFI = atrial flutter. The chemical structure of sotalol is shown here and is compared to two other important betaadrenergic blockers, propranolol and dichloroisoproterenol (DCI). Isoproterenol, the prototype of the beta agonist, is also shown for comparison. Sotalol differs from DCI primarily in the substitution of the methanesulfonanilid side chain in the para position. It differs from propranolol primarily by the absence of the naphthyl nucleus. cardiac patients with and without heart failure. Selected experiments were carried out in intact, closed-chest dogs to elucidate more critically its effects upon myocardial contractility within the intact circulation.
Methods

Selection of Patients
Twenty patients, ranging in age from 23 to 67 years, were studied in the postabsorptive state during diagnostic cardiac catheterization. Premedication, consisting of a single intramuscular injection of 10 mg of diazepam, was used in 14 patients to allay apprehension. The latter drug has been shown to cause only minimal and transient hemodynamic changes.'3 In all instances, the premedication preceded the measurement of the experimental data by at least 2 hours.
The patients' diagnoses and their functional classification, as defined by the New York Heart Association, are shown in table 1. All patients were symptomatic from their heart disease. Thirteen of the patients were moderately or severely symptomatic, being either class III or class IV. Fourteen of the patients were on digitalis at the time of the study. Informed consent to use the drug was obtained before each study.
Hemodynamic Technics
All pressure, rate, and flow measurements were made simultaneously. Cardiac output was determined by either the direct Fick method or by the indicator-dilution technic using indocyanine green injected into the pulmonary artery and sampling from a peripheral artery. During determination of the cardiac output, the following were measured: (1) heart rate and rhythm by the electrocardiogram; (2) systemic arterial, right heart, and pulmonary arterial pressures, by means of cardiac catheters attached to Statham P23D pressure transducers, with zero pressure at the level of the mid-right atrium, and (3) in 14 of the patients, left ventricular pressures were measured via the retrograde brachial approach; (4) systemic and pulmonary arterial blood saturation and capacity were determined spectrophotometrically*; (5) systemic arterial blood Po2, Pco2, and pH, by an electrode blood-gas analyzer,t utilizing duplicate *Model DU-2, Beckman Instruments, Inc., Palo Alto, California. tInstrumentation Laboratory, Inc., Boston, Massachusetts.
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The following hemodynamic variables were derived: 1. Stroke index, in ml/beat/m2 by using the formula:
CI/HR where CI = cardiac index in L/min/m2 HR = heart rate in beats/min. 2. Left ventricular minute work index, in kgm/min/M2, by using the formula:
where LVSPm = mean left ventricular systolic pressure in mm Hg LVEDP = left ventricular end-diastolic pressure in mm Hg CI = cardiac index in L/ min/m2 13.6 = conversion factor for the specific gravity of Hg 3. Tension-time index, in mm Hg sec/min by using the formula: TTI = LVSPm x HR x SEP where LVSPm = mean left ventricular systolic pressure in mm Hg (mean arterial systolic pressure substituted in cases without aortic stenosis) HR = heart rate in beats/min SEP = systolic ejection period in sec/ beat 4. Peripheral resistance, in dynes sec cm-5 by using the formula: P.Res. = mBA/ CO x 79.92 where mBA = mean arterial pressure in mm Hg CO = cardiac output in L/min 79.92 = conversion factor (mm Hg/L/min to dynes sec cm-5). After control measurements were recorded, sotalol was administered intravenously, in doses of 0.2, 0.4, or 0.6 mg/kg of body weight-doses considerably higher than that of 0.06 mg/kg, previously shown to cause in man a significant blockade of the tachycardia produced by 20,ug isoproterenol, intravenously.14 Each dose was injected at a constant rate over a 4-min interval, and measurements were made 10 min after the midpoint of the injection. Lead IL of the electrocardiogram and systemic arterial and venous pressures were monitored continuously during the 30 to 90-min period of observation involved in the study.
Blood samples were taken just before and 1 week after each study and were analyzed to detect any significant changes in the hemograms or liver and renal function tests.
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Experimental Canine Studies
To study more critically the effects of the drug on myocardial contractility, experiments were performed on two groups of healthy mongrel dogs of both sexes, ranging in weight from 15 to 23 kg. The animals were anesthetized intravenously with a warm solution of alpha-chloralose (80 mg/kg), after induction of anesthesia with a small intravenous injection of thiopental. Additional supplementary doses of the chloralose solution were given during the study to maintain a relatively uniform state of anesthesia, as judged by depression of corneal reflexes. However, no anesthetic agent was given after control measurements began. Respiration was maintained at a steady rate by a Harvard respiratory pump connected to a cuffed endotracheal tube, with steady supplemental oxygen administered to maintain optimal arterial blood oxygen saturation throughout the experiment.
Left ventricular pressure was measured through a short (4 in) 14-T gauge, semi-rigid Teflon needle* inserted percutaneously into the left ventricular apex and connected directly to a Statham P23Db pressure transducer without intervening tubing. The first derivative of left ventricular pressure (LV dp/dt) was computed electronically by means of an operational amplifiert and a resistance-capacitance differentiating circuit with a time constant of 0.05 msec and a frequency response which is linear to 150 cycles/sec. The circuit was calibrated for each experiment in terms of mm Hg/sec. Aortic blood pressure was measured at the arch of the aorta through a 13-gauge Teflon needle inserted into the right carotid artery. All recordings were made on an Electronics for Medicine, 8-channel photographic recorder. Group 
Three Dogs
To assess any changes produced by the drug upon myocardial contractility, the following technics were employed, analyzing the isovolumic portion of the left ventricular pressure trace and its simultaneously computed first derivative, taken from high speed (200 mm/sec) recordings. This method is based upon technics recently developed [15] [16] [17] [18] [19] [20] [21] [22] and allows a valid estimate of the contractile state of the heart within the intact circulation independent of changes in pre-load or after-load. Analysis of the isovolumic portion of systole was made using the calculation: LV dp/dt in sec- where p =left ventricular pressure in mm Hg LV dp/ dt = simultaneously measured rate of rise of pressure in mm Hg/ sec k = predetermined series elastic constant, 28, based on isolated muscle studies" and observations in the intact heart.24 A force-velocity curve was then determined by plotting the above quantity, at 4-msec intervals, against simultaneously measured left ventricular pressure, from the onset of ventricular contraction to the opening of the aortic valve. An index of the contractile state of the myocardium could then be determined either by extrapolation of the isovolumic segment of the force-velocity curve back to zero pressure load (Vmax) or by visual comparison of the two force-velocity curves before and after administration of the beta-blocking agent. In this group, 1.0 mg/kg of sotalol was used.
Group 2. Three Dogs
To assess any changes produced by the drug upon myocardial contractility in dogs independent of the basic, resting, intrinsic adrenergic drive, three dogs were pre-treated with 1.0 mg/kg reserpine, intravenously, 18 to 24 hr prior to the experiment. Force-velocity curves were determined, as in group 1, before and after graded doses of sotalol up to a maximum dose of 6.0 mg/kg. In both groups of dogs, heart rates were held constant throughout each experiment by means of a unipolar pacing catheter introduced into the mid-right atrium.
Results
Studies in Man
The effects of graded doses of sotalol upon resting hemodynamics are shown, for all patients, in table 1. Figures 2 to 4 show graphically the changes in selected hemodynamics produced by the drug. The dose used in each patient is indicated according to the key in each figure, with the averages for the three doses (before and after beta blockade) shown in the respective margins. Patients in heart failure are indicated by dotted lines.
Heart rate (fig. 2 ) decreased significantly in all patients and at all doses. The average change for the 0.2 mg/kg dose was approximately 15% below control level and for the 0. .".2
Hg. As seen in table 1, these patients had other hemodynamic evidence of left heart failure and all were either moderately or severely symptomatic (class III or IV). The effect upon left ventricular end-diastolic pressure following sotalol is shown graphically in figure 3 . Note that in all but one of the patients there was no significant increase. Arteriovenous oxygen difference widened in all of the 11 patients in whom it was measured, indicating an increased oxygen extraction. Changes in oxygen consumption were small and variable, and the average change at all doses was insignificant.
Mean arterial pressure was not significantly altered at any of the three dose levels of the drug. Systolic pressure decreased in almost all of the patients with a significant average decrease for all patients.
Changes in tension-time index and left ventricular minute work are shown graphically in figure 4 . There were significant decreases in both parameters consistent with a reduction in myocardial oxygen consumption. Figure 5 is a composite graph showing the average hemodynamic changes produced by sotalol-induced blockade, plotted in terms of percent change from control at each of the three dose levels. Heart rate, cardiac index, and tension-time index fell significantly to a maximum decrease of approximately 20% below control at the 0.4 mg/kg dose, beyond which there was no further change. Peripheral resistance rose uniformly in an equal amount after the 0.4 mg/kg dose, and there was no further effect by the 0.6 mg/kg dose. These data show that although significant beta blockade occurred at the 0.2 mg/kg dose, the peak hemodynamic effect of sotalol in humans was obtained by 0.4 mg/kg. Changes in pulmonary artery pressures were small and variable. In three patients (J.B., F.B., and M.S.), all of whom had predominantly mitral stenosis, pulmonary capillary wedge pressure was measured. In all three, there was a slight decrease in wedge pressure. This was, however, accompanied by small increases in calculated pulmonary vascular resistance (380 to 460, 290 to 410, and 650 to 800 dynes sec cm-5, respectively), which was related to the reduction of cardiac output. There were no significant changes in right atrial pressure in any of the patients. The patient with the highest right atrial pressure (L.K., 19 mm Hg) received 0.6 mg/kg of sotalol. No A series of force-velocity, curves, calculated as described in the text, for six different dogs, with hearts paced at constant rates. Doses used in each dog are indicated in the key. No significant downward shift in force-velocity relationship occurred in any of the dogs even with the larger doses, indicating that there was no measurable change in the contractile state of the intact heart.
Nine of the patients had chronic atrial fibrillation, one had paroxysmal atrial flutter with an atrial to ventricular ratio of 4:1, and one had second degree atrioventricular block, with dropped beats (Wenckebach phenomenon), at the time of study. The induction of beta blockade produced only a slowing of the ventricular rate in those patients with atrial fibrillation, with no instance of conversion to sinus rhythm. There was an equal slowing of atrial and ventricular rates in the patient with atrial flutter with maintenance of the 4:1 ratio. The patient with the Wenckebach phenomenon had a mild slowing of atrial and ventricular rates (96 to 90/min) with no change in the rate of dropped beats.
None of the patients experienced any adverse effects from the drug or changes in symptomatology. The period of observation following administration of the drug lasted from 2 to 6 hours. There were no adverse or deleterious changes in the hemogram or in Circulation, Volume XLII, July 1970 liver or renal function tests over the 1-week period following administration of the drug. Figure 6 is a composite graph showing a series of force-velocity curves in six dogs, comprising the paced-normal dogs (group 1) in the panel on the left and the pacedreserpinized dogs (group 2) on the right. The open symbols represent various doses of sotalol as indicated in the key. In all studies there was no downward shift in the forcevelocity relationship, even at doses far above the beta-blocking dose-indicating no measurable basic change in the contractile state of the intact heart at controlled heart rates. Discussion These data extend to the intact circulation and to cardiac patients the previous find-ings2' 12 on isolated cardiac muscle showing that sotalol-induced beta-adrenergic blockade is not accompanied by myocardial depressant effects. In the 14 patients in whom left heart catheterizations were performed, including eight patients with left heart failure, stroke output, mean arterial pressure, and left ventricular end-diastolic pressure remained essentially unchanged. No measurable deleterious effect upon resting cardiac dynamics was indicated, even in those patients who had faradvanced heart failure. The one exception was a patient (D.B.) in the group without heart failure, with isolated aortic regurgitation, in whom the left ventricular end-diastolic pressure rose from 10 to 14 mm Hg.
Experimental Canine Studies
In the experimental canine studies it was possible to examine more critically any changes in ventricular contractility during sotalol-induced beta blockade. By maintaining a constant heart rate with atrial pacing, it was possible to evaluate the contractile state without associated rate-related changes. The use of the force-velocity relationship allowed an evaluation of the effect of the drug independent of subtle changes in ventricular pre-load or after-load. Use of these technics in both normal and reserpinized dogs made it possible to draw conclusions regarding effects on the normal and catecholamine-depleted myocardium. In each case there was no downward shift in the force-velocity curve, indicating that no change had been induced in the contractile state of the myocardium by beta blockade with this agent.
These results with sotalol are in sharp contrast to several studies reported in the literature using pronethalol or propranolol, in which beta blockade in man caused significant increases in filling pressures7' 9 and decreases in stroke output. [7] [8] [9] 25 The beta-blocking potency ratio of propranolol to sotalol has been found to be approximately 5:1 in the intact dog.6 Assuming that this ratio holds true in man, the larger doses of sotalol used in these studies are equipotent to the doses used in most of the propranolol studies in man. The explanation for the important difference in hemodynamic response between sotalol and propranolol may be the presence of the negative inotropic or myocardial depressant effects of the latter. Levy and Richards,12 studying the structureactivity relationship of beta-adrenergic antagonists, noted that those compounds containing the naphthyl nucleus within their chemical structure had a potent myocardial depressant effect as well as local anesthetic action.
Because of this depressant effect, understandably, there are no comparable studies in which propranolol has been given intravenously to patients with severe congestive heart failure, so that comparison of propranolol and sotalol in this circumstance is not possible. Epstein and Braunwald26 gave propranolol orally to patients in clinical heart failure, while on a controlled sodium diet. They found that over a period of weeks, increasing doses of propranolol caused sodium and water retention and worsened the heart failure. It was not determined, however, whether the observed sodium retention was due to the intrinsic myocardial depression of propranolol, its interference with the beta-adrenergic drive on the heart, or actual blockade of the sodium excretory function of the nephron.
The data in this study raise the important question regarding the actual role of circulating catecholamines in maintaining the failing myocardium from further decompensation.
Several recent studies have shown that with heart failure, important alterations occur in the normal relationship between intrinsic catecholamines and the contractile response of the heart. It has been shown that early in the course of heart failure, myocardial stores of norepinephrine become diminished.27 Norepinephrine release in response to adrenergic neural stimulation also decreases.28 Plasma levels of norepinephrine increase,27 29 and the myocardium becomes more sensitive to exogenous catecholamines.30 It is not clear, however, to what extent the chronically failing myocardium-relatively late in its course, and already operating at a chronically elevated ventricular filling pressure and reduced stroke volume-depends on these increased resting levels of plasma catecholamines to maintain its remaining contractile integrity. Our data do not support the assumption that the heart depends greatly on this resting catecholamine drive. The eight patients with chronically failing hearts underwent beta blockade with a significant drop in heart rate and cardiac output. They were apparently able to tolerate this through increased oxygen extraction and further widening of arteriovenous oxygen difference. The most striking example of this was patient M.S. (table 1) who had an extremely low resting cardiac index of 1.4 L/min/m2. In spite of an already marked arteriovenous oxygen difference of 100 ml/L, beta blockade produced an even further widening of the oxygen difference to 121 ml/L with no change in left or right ventricular filling pressure, stroke index, or mean arterial pressure. The marked widening of arteriovenous oxygen difference was not accompanied by discernible untoward symptoms. Furthermore) in the reserpinized dogs whose ventricular contraction characteristics are similar to those of the failing myocardium,31 beta blockade produced no significant change in the force-velocity relationship when ventricular rates were held constant. It may be argued that since beta blockade is a simple one-to-one competitive inhibition at the receptor site, larger doses of blocking agent would be required to override the higher catecholamine levels in the patient with heart failure. Our data do not support this assumption since peak hemodynamic effects occurred at the 0.4 mg/kg dose rather than the 0.6 mg/kg dose.
It appears evident from these studies with sotalol that acute beta blockade-in the abscence of associated nonspecific myocardial depression-does not sufficiently impair cardiac function to produce observable deleterious changes in the resting hemodynamics of patients with advanced chronic heart failure. The findings suggest also that the heart in advanced chronic failure may not depend heavily on intrinsic resting catecholamine drive to maintain its contractile response. 
